Nabi Biopharmaceuticals
Nabi Biopharmaceuticals was a Rockville, Maryland-based biopharmaceutical company developing preventive measures and treatments for diseases; it is now delisted from NASDAQ, operates with 1-10 employees, and shows no active products, customers, or revenue in the input data.
- Company typePrivate
- Founded1967
- HeadquartersRockville, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
What Nabi Biopharmaceuticals does
Nabi Biopharmaceuticals is a for-profit biopharmaceutical company historically focused on developing preventive measures and treatments for diseases, headquartered in Rockville, Maryland, and originally founded in 1967. The company previously traded on NASDAQ under the ticker symbol NABI but is now delisted, and the current input indicates a contracted headcount of 1-10 employees with no active management team, product portfolio, customer base, pricing model, or revenue stream documented in the supplied material. The corporate web property at nabi.com currently resolves to a Markmonitor domain-inquiry landing page indicating the domain may be for sale, and no clinical pipeline, regulatory filings, partnerships, or technology stack are present in the input. The only dated capital-formation event on record is a single funding round of $10,000,000 on 2009-09-29 with unspecified investors and lead, and the broader ownership, subsidiary, and operating-geography fields are empty.
Taken together, the available evidence describes Nabi Biopharmaceuticals as either a dormant shell or a minimally staffed residual entity rather than an operating biopharmaceutical business. There is no disclosed go-to-market motion, distribution channel, revenue model, or product surface from which to derive current commercial activity. Strategic value, if any, would reside in legacy intellectual property, biologic assets, or trademarks not enumerated in the current dataset, but none of these are visible in the input and therefore cannot be characterized with confidence. The data gap is significant: the input does not confirm whether the entity is in active wind-down, has been acquired and is operating under a different banner, or retains any latent licensable assets, so any investment thesis should be built around confirmation of those unknowns before valuation.
Nabi Biopharmaceuticals firmographics
Firmographics- Name
- Nabi Biopharmaceuticals
- Website
- https://nabi.com
- Company type
- Private
- Founded year
- 1967
- Headcount range
- 1–10 employees
- Short description
- Nabi Biopharmaceuticals was a Rockville, Maryland-based biopharmaceutical company developing preventive measures and treatments for diseases; it is now delisted from NASDAQ, operates with 1-10 employees, and shows no active products, customers, or revenue in the input data.
- Ownership category
- akta.pro rank
Nabi Biopharmaceuticals industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Infectious Disease & Antimicrobials Pharmaceuticals (HLAIAAAG)
- akta.pro secondary industry
- Immunology & Inflammation Pharmaceuticals (HLAIAAAD)
Keywords
Where Nabi Biopharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Rockville
- HQ country
- United States
- HQ region
- North America
Markets served
Nabi Biopharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Nabi Biopharmaceuticals product offering
Product offeringCore offering
Nabi Biopharmaceuticals develops preventive measures and treatments for diseases. The company is a biopharmaceutical firm focused on creating biological products for disease prevention and therapeutic intervention. Its historical operations have centered on pharmaceutical R&D and product commercialization.
Differentiator
Problem solved
Functional benefit
Companies that use Nabi Biopharmaceuticals
Customer profileIdeal customer profiles1 record
Nabi Biopharmaceuticals technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Nabi Biopharmaceuticals partnerships and signals
Strategic signalRecent moves4 records
Nabi Biopharmaceuticals competitors and assessment
Company assessmentDirect peers
- Bavarian Nordic: Vaccine-focused biotechnology company specializing in infectious disease and biodefense, directly comparable to Nabi's historical vaccine franchise.
- Dynavax Technologies: Specialty vaccine developer with adjuvanted and immune-modulating products targeting infectious disease, comparable to Nabi's vaccine and immune-based product strategy.
- VBI Vaccines: Smaller specialty vaccine developer focused on infectious disease and immuno-oncology, with a similar scale profile and pipeline orientation to Nabi's historical scope.
- Emergent BioSolutions: Specialty vaccines and antibody therapeutics developer historically focused on infectious disease and biodefense, directly overlapping Nabi's historical portfolio of vaccines and immune globulins.
- Novavax: Vaccine-focused biotechnology company developing immunogenic products for infectious diseases, sharing Nabi's historical focus on prophylactic biologics.
Broad incumbents
- Merck & Co. Large pharmaceutical incumbent with a substantial vaccines and infectious disease franchise, operating as a broad competitor to specialty players like Nabi across overlapping indications.
- GSK: Global biopharma incumbent with one of the largest vaccine portfolios, competing directly with smaller specialty vaccine developers in infectious disease.
- Sanofi Pasteur: The vaccines division of Sanofi, a global incumbent offering an extensive infectious disease vaccine portfolio that overlaps with the therapeutic categories Nabi historically targeted.
Market position
Strengths2 records
Weaknesses3 records
Competitive moat2 records
Key risks4 records
Key highlights3 records
Customer concentration
Nabi Biopharmaceuticals social profiles
Digital presenceNabi Biopharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nabi Biopharmaceuticals leadership team
Management profileNumber of profiles
Nabi Biopharmaceuticals funding detail
Funding detailFunding overview
Funding rounds1 record
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nabi Biopharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nabi Biopharmaceuticals
What does Nabi Biopharmaceuticals do?
Nabi Biopharmaceuticals develops preventive measures and treatments for diseases. The company is a biopharmaceutical firm focused on creating biological products for disease prevention and therapeutic intervention. Its historical operations have centered on pharmaceutical R&D and product commercialization.
When was Nabi Biopharmaceuticals founded?
Nabi Biopharmaceuticals was founded in 1967. It employs 1 to 10 people.
Where is Nabi Biopharmaceuticals based?
Nabi Biopharmaceuticals is headquartered in Rockville, United States, in the North America region.
Who are Nabi Biopharmaceuticals's main competitors?
Direct peers on record are Bavarian Nordic, Dynavax Technologies, VBI Vaccines, Emergent BioSolutions and Novavax. Broad incumbents are Merck & Co., GSK and Sanofi Pasteur.
Does Nabi Biopharmaceuticals have an API?
No public API is recorded for Nabi Biopharmaceuticals.
What industry is Nabi Biopharmaceuticals in?
Nabi Biopharmaceuticals's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIAAAG, Infectious Disease & Antimicrobials Pharmaceuticals, with a secondary code of HLAIAAAD, Immunology & Inflammation Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.